← Leaderboards
Srinivasan Dasarathy
Cleveland Clinic Lerner Com-Cwru
$21,059,442
Attributed
$26,137,734
Total exposure
16
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,607,135 · 15
AHRQ$1,530,599 · 1
By mechanism
U01$12,186,877 · 3
R01$10,498,928 · 6
P50$2,581,532 · 3
R21$808,716 · 2
P20$59,872 · 1
M01$1,809 · 1
Top collaborators
- Arthur J Mccullough6 shared
- Laura E. Nagy5 shared
- Maria Hatzoglou4 shared
- Michael B Rothberg4 shared
- Gangarao Davuluri2 shared
- David Streem2 shared
Most similar at Cleveland Clinic Lerner Com-Cwru
Same institution · by research overlap
- Gangarao Davuluri$199,289
Others in their field
Top investigators on “Liver Diseases”
- David Heimbrook · Leidos Biomedical Research, Inc.$183,557,534
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Richard Douglas Moore · Johns Hopkins University$59,048,354
- Paul M. Ridker · Brigham And Women'S Hospital$55,416,022
- Michael S. Saag · University Of Alabama At Birmingham$50,288,385
- Larry Arthur$49,271,333
Research focus
Liver DiseasesSarcopeniaResponseAffectLiverMuscleCirrhosisMuscular AtrophyClinical TrialsReportingFundingBaseTherapeutic TargetImpairmentMuscle FormPathway InteractionsAmmoniaAlcoholsProtein BiosynthesisFoundationsMortalityRandomizedPlasmaMolecular
Grant awards (71)
Prospective evaluation of outcomes in cirrhosis of different etiologies: impact of HIV infection and simvastatin therapy$733,101
U01 · FY2025 · DK · contact PI
Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD)- Cleveland Clinic Clinical Center$354,195
U01 · FY2025 · AA · contact PI
Mechanistic basis of exercise responses in liver disease$296,183
R01 · FY2025 · DK · contact PI
Project 3 Title: Sarcopenia of ALD: regulation of skeletal muscle autophagy by alcohol$273,436
P50 · FY2025 · AA · contact PI
Continuation of the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Clinical Center-Cleveland site$249,613
U01 · FY2025 · DK · contact PI
Prospective evaluation of outcomes in cirrhosis of different etiologies: impact of HIV infection and simvastatin therapy$733,101
U01 · FY2024 · DK · contact PI
Novel mechanism based treatment to improve tissue injury in alcoholic hepatitis$553,183
R01 · FY2024 · AA · contact PI
Modeling the Disease Burden and Cost-Effectiveness of Screening and Treatment for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Patients$367,899
R01 · FY2024 · HS
Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD)- Cleveland Clinic Clinical Center$354,195
U01 · FY2024 · AA · contact PI
Mechanistic basis of exercise responses in liver disease$275,231
R01 · FY2024 · DK · contact PI
Project 3 Title: Sarcopenia of ALD: regulation of skeletal muscle autophagy by alcohol$273,436
P50 · FY2024 · AA · contact PI
Prospective evaluation of outcomes in cirrhosis of different etiologies: impact of HIV infection and simvastatin therapy$256,221
U01 · FY2024 · DK · contact PI
Continuation of the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Clinical Center-Cleveland site$250,000
U01 · FY2024 · DK · contact PI
Non Alcoholic Steatohepatitis Clinical Research Network$668,701
U01 · FY2023 · DK · contact PI
Prospective evaluation of outcomes in cirrhosis of different etiologies: impact of HIV infection and simvastatin therapy$584,736
U01 · FY2023 · DK · contact PI
Novel mechanism based treatment to improve tissue injury in alcoholic hepatitis$554,644
R01 · FY2023 · AA · contact PI
Modeling the Disease Burden and Cost-Effectiveness of Screening and Treatment for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Patients$384,387
R01 · FY2023 · HS
Mechanistic basis of exercise responses in liver disease$291,134
R01 · FY2023 · DK · contact PI
Project 3 Title: Sarcopenia of ALD: regulation of skeletal muscle autophagy by alcohol$276,867
P50 · FY2023 · AA · contact PI
ALCOHOLIC HEPATITIS CLINICAL AND TRANSLATIONAL NETWORK: LATE PHASE CLINICAL TRIALS AND OBSERVATIONAL STUDIES6/9$99,999
U01 · FY2023 · AA · contact PI
Non Alcoholic Steatohepatitis Clinical Research Network$618,611
U01 · FY2022 · DK · contact PI
Prospective evaluation of outcomes in cirrhosis of different etiologies: impact of HIV infection and simvastatin therapy$590,081
U01 · FY2022 · DK · contact PI
Novel mechanism based treatment to improve tissue injury in alcoholic hepatitis$557,780
R01 · FY2022 · AA · contact PI
Modeling the Disease Burden and Cost-Effectiveness of Screening and Treatment for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Patients$389,221
R01 · FY2022 · HS
Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 6/9$369,000
U01 · FY2022 · AA · contact PI
Project 3 Title: Sarcopenia of ALD: regulation of skeletal muscle autophagy by alcohol$279,345
P50 · FY2022 · AA · contact PI
Non Alcoholic Steatohepatitis Clinical Research Network$645,943
U01 · FY2021 · DK · contact PI
Sarcopenia in cirrhosis is mediated by a hyperammonemic stress response$579,497
R01 · FY2021 · DK · contact PI
Novel mechanism based treatment to improve tissue injury in alcoholic hepatitis$557,780
R01 · FY2021 · AA · contact PI
Modeling the Disease Burden and Cost-Effectiveness of Screening and Treatment for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Patients$389,092
R01 · FY2021 · HS
Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 6/9$383,666
U01 · FY2021 · AA · contact PI
Prospective evaluation of outcomes in cirrhosis of different etiologies: impact of HIV infection and simvastatin therapy$379,411
U01 · FY2021 · DK · contact PI
Project 3 Title: Sarcopenia of ALD: regulation of skeletal muscle autophagy by alcohol$279,345
P50 · FY2021 · AA · contact PI
Non Alcoholic Steatohepatitis Clinical Research Network$652,507
U01 · FY2020 · DK · contact PI
Sarcopenia in cirrhosis is mediated by a hyperammonemic stress response$579,497
R01 · FY2020 · DK · contact PI
Novel mechanism based treatment to improve tissue injury in alcoholic hepatitis$557,780
R01 · FY2020 · AA · contact PI
Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 6/9$383,958
U01 · FY2020 · AA · contact PI
Mechanisms of Malnutrition in Cirrhosis with Portosystemic Shunting$304,842
R01 · FY2020 · GM · contact PI
Project 3: Sarcopenia of ALD: Regulation of Skeletal Muscle Autophagy by Alcohol$244,899
P50 · FY2020 · AA · contact PI
ALCOHOLIC HEPATITIS CLINICAL AND TRANSLATIONAL NETWORK: LATE PHASE CLINICAL TRIALS AND OBSERVATIONAL STUDIES 6/9$153,563
U01 · FY2020 · AA · contact PI
Sarcopenia in cirrhosis is mediated by a hyperammonemic stress response$575,898
R01 · FY2019 · DK · contact PI
Non Alcoholic Steatohepatitis Clinical Research Network$538,178
U01 · FY2019 · DK · contact PI
Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 6/9$383,608
U01 · FY2019 · AA · contact PI
Mechanisms of Malnutrition in Cirrhosis with Portosystemic Shunting$304,769
R01 · FY2019 · GM · contact PI
Project 3: Sarcopenia of ALD: Regulation of Skeletal Muscle Autophagy by Alcohol$244,899
P50 · FY2019 · AA · contact PI
Sarcopenia in cirrhosis is mediated by a hyperammonemic stress response$575,898
R01 · FY2018 · DK · contact PI
Non Alcoholic Steatohepatitis Clinical Research Network$451,317
U01 · FY2018 · DK
Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 6/9$369,000
U01 · FY2018 · AA · contact PI
Mechanisms of Malnutrition in Cirrhosis with Portosystemic Shunting$315,240
R01 · FY2018 · GM · contact PI
Project 3: Sarcopenia of ALD: Regulation of Skeletal Muscle Autophagy by Alcohol$219,508
P50 · FY2018 · AA · contact PI
Hyperammonemia reduces skeletal muscle protein synthesis via a beta-catenin-cMyc mediated impaired ribosomal biogenesis$212,418
R21 · FY2018 · AR · contact PI
Alcoholic Hepatitis Clinical and Translational Network - Late Phase Clinical Trials and Observational Studies (Collaborative U01)$8,428
U01 · FY2018 · AA · contact PI
Non Alcoholic Steatohepatitis Clinical Research Network$474,529
U01 · FY2017 · DK
Mechanisms of Malnutrition in Cirrhosis with Portosystemic Shunting$323,340
R01 · FY2017 · GM · contact PI
Project 3: Sarcopenia of ALD: Regulation of Skeletal Muscle Autophagy by Alcohol$244,898
P50 · FY2017 · AA · contact PI
Hyperammonemia reduces skeletal muscle protein synthesis via a beta-catenin-cMyc mediated impaired ribosomal biogenesis$186,160
R21 · FY2017 · AR
Non Alcoholic Steatohepatitis Clinical Research Network$501,622
U01 · FY2016 · DK
Project 3: Sarcopenia of ALD: Regulation of Skeletal Muscle Autophagy by Alcohol$244,899
P50 · FY2016 · AA · contact PI
Non Alcoholic Steatohepatitis Clinical Research Network$579,283
U01 · FY2015 · DK
Mechanisms of Malnutrition in Cirrhosis with Portosystemic Shunting$339,536
R01 · FY2015 · DK · contact PI
Alcohol induces muscle autophagy by a novel AMPK independent PI3K mediated mechan$179,928
R21 · FY2015 · AA · contact PI
Non Alcoholic Steatohepatitis Clinical Research Network$44,766
U01 · FY2015 · DK
Non Alcoholic Steatohepatitis Clinical Research Network$375,544
U01 · FY2014 · DK
Mechanisms of Malnutrition in Cirrhosis with Portosystemic Shunting$339,603
R01 · FY2014 · DK · contact PI
Alcohol induces muscle autophagy by a novel AMPK independent PI3K mediated mechan$230,210
R21 · FY2014 · AA · contact PI
Mechanisms of Malnutrition in Cirrhosis with Portosystemic Shunting$327,777
R01 · FY2013 · DK · contact PI
Mechanisms of Malnutrition in Cirrhosis with Portosystemic Shunting$339,696
R01 · FY2012 · DK · contact PI
Mechanisms of Malnutrition in Cirrhosis with Portosystemic Shunting$419,021
R01 · FY2011 · DK · contact PI
Pilot Project$30,226
P20 · FY2010 · AA · contact PI
Pilot Project$29,646
P20 · FY2009 · AA · contact PI
RANDOMIZED CONTROLLED TRIAL OF OMEGA 3 FATTY ACIDS IN THE TREATMENT$1,809
M01 · FY2007 · RR · contact PI